About: 1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: 1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 February 1989

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в лютому 1989 (uk) im Februar 1989 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en febreru de 1989 (ast) artikull shkencor i botuar më 01 shkurt 1989 (sq) scientific article published on 01 February 1989 (en)
publication date	wds:Q69496651-94D9CA28-F986-42F7-8CDF-BD0C22381060
publication date	1989-02-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q69496651-FD5A8210-DDE5-4686-B045-092A9731B16E
language of work or name	English
exact match	wds:Q69496651-1CF3D676-8FE8-4C93-BE4C-9A1052E9D609
exact match	https://scigraph.springernature.com/pub.10.1038/ki.1989.36
cites work	wds:Q69496651-19811C39-210B-4A0F-922B-025ED4D46371 wds:Q69496651-348DABA6-592B-4E7D-B0EB-375FE0208163 wds:Q69496651-38186AAB-6C59-4C85-9C35-B4D665BCD469 wds:Q69496651-3F9B25C6-D7DC-4F8B-B1E3-F48F2D6910A2 wds:Q69496651-52BE5B2A-2ACF-411D-A694-A2D440DB39E7 wds:Q69496651-53E7A030-83F0-472E-93F0-C7D859C696D8 wds:Q69496651-6A8BEBD4-C78C-47A9-9DF4-21AA9B88CA5D wds:Q69496651-6E9193EE-51DF-42A9-9A8F-8B4DEAD4EF45 wds:Q69496651-893318A9-71BB-4120-9E08-14F2E906C2C0 wds:Q69496651-8ACCE35B-75CF-43D4-9395-8CA507C6DED8 wds:Q69496651-A5DDC302-06A3-4C67-80EA-0FED3579F476 wds:Q69496651-A628656A-9D7C-4198-B67E-8145E5110EC2 wds:Q69496651-AFCA727E-F064-40E7-B368-F4A815D5EA92 wds:Q69496651-C2C76265-B07C-4DE8-82E6-0E7DAB7E6B18 wds:Q69496651-D4A304DE-16C8-4413-A883-CEC657160FD8 wds:Q69496651-D94B376B-B114-46CD-A131-BE5ED211D0B2 wds:Q69496651-EF625B8E-5099-47CA-8787-227D408D1CF0 wds:Q69496651-F20E8761-C335-4D0F-87F6-3EB550C89F77 wds:Q69496651-F6E78EE3-265D-4C3A-A247-2C692D0259AA
cites work	Reduced plasma concentration of 1,25-dihydroxyvitamin D in children with moderate renal insufficiency Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol Double-blind trial of oral 1,25-dihydroxy vitamin D3 versus placebo in asymptomatic hyperparathyroidism in patients receiving maintenance haemodialysis. Controlled trial of 1apha-hydroxycholecalciferol in chronic renal failure Effects of long-term therapy with calcitriol in patients with moderate renal failure A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromatography: application to clinical studies A new semiautomatic method for quantitative static and dynamic bone histology Determinants of serum 1,25(OH)2D levels in renal disease Bone histology in incipient and advanced renal failure Calcitriol, parathyroid hormone, and accumulation of aluminum in bone in dogs with renal failure No 1,25-dihydroxyvitamin D3 receptors on osteoclasts of calcium-deficient chicken despite demonstrable receptors on circulating monocytes Altered divalent ion metabolism in early renal failure: role of 1,25(OH)2D Aluminum-related bone disease in mild and advanced renal failure: evidence for high prevalence and morbidity and studies on etiology and diagnosis 1,25-Dihydroxyvitamin D maintains bone cell activity, and parathyroid hormone modulates bone cell number in dogs Vitamin-D poisoning: survey of causes in 21 patients with hypercalcaemia Bone GLA protein in predialysis chronic renal failure. Effects of 1,25(OH)2D3 administration in a long-term follow-up Plasma levels of vitamin D metabolites in renal diseases Is 1,25-dihydroxy-cholecalciferol harmful to renal function in patients with chronic renal failure? Calcitriol treatment does not increase the serum aluminium concentration in patients with moderate renal failure
author name string	wds:Q69496651-0EBAB404-B78F-4564-9BAA-43E872429DE6 wds:Q69496651-1F05323A-8BF6-47AC-A8C3-2B91204EE663 wds:Q69496651-2BB0465C-4E4A-4D07-B855-E1F8A473C959 wds:Q69496651-3A52A273-D995-45FC-B355-67F458498BF8 wds:Q69496651-43593882-F6FA-4812-A842-ECE50855CFD9 wds:Q69496651-6617316E-0B73-4E65-A449-44F989FC286E wds:Q69496651-6B5C7D82-B559-4837-9B26-3A8FB7685358
author name string	L R Baker H H Malluche P Fanti L Abrams M C Faugere C J Roe Y Subayti
rdfs:label	1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial (en) 1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial (nl) 1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial (sq)
skos:prefLabel	1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial (en) 1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial (nl) 1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial (sq)
name	1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial (en) 1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial (nl) 1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial (sq)
title	wds:Q69496651-8DD771D9-388C-472F-B34F-21F0396F94CC
title	1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial (en)
page(s)	wds:Q69496651-103FB546-D854-46A1-9E5E-D379E34A964B
page(s)	661-669
instance of	wds:Q69496651-AED0C660-E2DE-4938-AFD4-BBEF6686C426
instance of	scholarly article
PubMed ID	wds:Q69496651-D4B6D5E6-309A-4C92-8473-0905C1580781
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/2651758
PubMed ID	2651758
published in	wds:Q69496651-039B5B57-35FF-4E56-A3C0-CAFB5F799CE5
published in	Kidney International
issue	wds:Q69496651-A106F653-2F44-4BDF-A4FE-9F9AB1A6DCFA
volume	wds:Q69496651-BD48CC62-9DAF-4F0C-842D-FE4B1ADFB644
issue	2
volume	35
DOI	wds:Q69496651-E2D2623A-8168-46D0-ABBE-2999A27992BC
DOI	http://dx.doi.org/10.1038/KI.1989.36
DOI	10.1038/KI.1989.36
Dimensions Publication ID	wds:Q69496651-7E5BC0BF-F138-4E42-95BE-0F878C44124F
Dimensions Publication ID	1007335554
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q69496651
is cites work of	Endocrine abnormalities in chronic renal failure Treatment options of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease stages 3 and 4: an historic review Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 194 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software